Gene · 5819
Papers2,573
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,573
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Treg in inborn errors of immunity: gaps, knowns and future perspectives. | Front Immunol | 2023 | 38259469 | PubTator, text mining | PubMed |
| Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles. | Proteomes | 2023 | 38250812 | PubTator, text mining | PubMed |
| Current status and future perspective of natural killer cell therapy for cancer. | Med Rev (2021) | 2023 | 38235405 | PubTator, text mining | PubMed |
| Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis. | Cancers (Basel) | 2023 | 38201595 | PubTator, text mining | PubMed |
| Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. | Front Immunol | 2023 | 38193082 | PubTator, text mining | PubMed |
| Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity. | Front Immunol | 2023 | 38143742 | PubTator, text mining | PubMed |
| Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response. | Cell Rep Med | 2023 | 38118407 | PubTator, text mining | PubMed |
| IER5L is a Prognostic Biomarker in Pan-Cancer Analysis and Correlates with Immune Infiltration and Immune Molecules in Non-Small Cell Lung Cancer. | Int J Gen Med | 2023 | 38106972 | PubTator, text mining | PubMed |
| Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities. | J Hematol Oncol | 2023 | 38104104 | PubTator, text mining | PubMed |
| Killer instincts: natural killer cells as multifactorial cancer immunotherapy. | Front Immunol | 2023 | 38090565 | PubTator, text mining | PubMed |
| Host cellular factors involved in pseudorabies virus attachment and entry: a mini review. | Front Vet Sci | 2023 | 38089700 | PubTator, text mining | PubMed |
| A single-cell atlas of the peripheral immune response in patients with influenza A virus infection. | iScience | 2023 | 38089584 | PubTator, text mining | PubMed |
| Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies. | J Immunother Cancer | 2023 | 38081778 | PubTator, text mining | PubMed |
| CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects. | Cells | 2023 | 38067178 | PubTator, text mining | PubMed |
| The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies. | Cancer Cell Int | 2023 | 38057843 | PubTator, text mining | PubMed |
| GARP and EARP are required for efficient BoHV-1 replication as identified by a genome wide CRISPR knockout screen. | PLoS Pathog | 2023 | 38055775 | PubTator, text mining | PubMed |
| TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. | iScience | 2023 | 38053639 | PubTator, text mining | PubMed |
| Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. | Cancer Med | 2023 | 38037752 | PubTator, text mining | PubMed |
| An association between ATP7B expression and human cancer prognosis and immunotherapy: a pan-cancer perspective. | BMC Med Genomics | 2023 | 38037104 | PubTator, text mining | PubMed |
| Towards a comprehensive view of the herpes B virus. | Front Immunol | 2023 | 38035092 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5819/papers?page=13